Complement system
Complement factor H
Complement factor H (CFH) is a plasma glycoprotein present at a concentration of approximately 300 az 800 mg/L and a key regulator of the alternative complement pathway.

O patogenu
Complement factor H (CFH) is a plasma glycoprotein present at a concentration of approximately 300 az 800 mg/L and a key regulator of the alternative complement pathway. It limits amplification of the complement cascade, promotes C3b inactivation, and protects host cell surfaces from complement-mediated damage. Autoantibodies against factor H, often directed against its C-terminal region, may impair CFH binding to host cell surfaces and cause an acquired functional deficiency. This can result in uncontrolled complement activation, endothelial injury, and the development of thrombotic microangiopathy, even when total factor H concentrations remain within the normal range.
Anti-CFH autoantibodies are most strongly associated with atypical hemolytic uremic syndrome (aHUS), now classified among complement-mediated thrombotic microangiopathies (TMA). They are detected in approximately 10% of patients with aHUS, which is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Quantitative measurement of anti-CFH IgG is therefore an important component of the differential diagnosis in suspected complement-mediated TMA and is also valuable for patient follow-up, as changes in antibody titers may help assess response to immunosuppressive therapy and the risk of relapse. Results should always be interpreted together with the clinical picture and other parameters of the complement system.
VIDIA brings a globally unique solution: ELISA-VIDITEST anti-complement factor H IgG is the only commercially available CE-IVD assay for the quantitative determination of anti-CFH IgG antibodies.
Portfolio
Dostupné assays
Portfolio pro tento patogen průběžně doplňujeme. Napište nám na obchod@vidia.cz a pošleme dostupné varianty.
Časté otázky
Často kladené otázky
What is complement factor H and why are anti-CFH antibodies tested?
Complement factor H (CFH) is one of the key negative regulators of the alternative complement pathway. It limits uncontrolled C3 activation and helps protect the body's own cell surfaces from complement-mediated damage. Autoantibodies against factor H can disrupt this regulatory function and lead to uncontrolled activation of the alternative complement pathway. The most significant clinical association is autoantibody-mediated atypical hemolytic uremic syndrome (aHUS), characterized by thrombotic microangiopathy, microangiopathic hemolytic anemia, thrombocytopenia and kidney damage. VIDIA ELISA-VIDITEST is intended for quantitative determination of anti-CFH IgG in serum and plasma.
What does a positive anti-CFH IgG finding mean in a patient with suspected aHUS?
A positive anti-CFH IgG result supports a diagnosis of autoimmune-mediated complement dysregulation and can help identify a specific subgroup of aHUS patients. The result is not, however, a standalone diagnostic criterion and must be interpreted in the context of the clinical picture of thrombotic microangiopathy and other investigations, particularly hematological, renal, complement, and, depending on the situation, genetic and differential diagnostic tests. Screening aHUS patients for anti-factor H antibodies is considered an important part of a comprehensive complement workup.
How is the test result used to monitor response to treatment?
The advantage of quantitative determination is the ability to track the development of anti-CFH antibody concentration over time. A decline in titer after immunomodulatory treatment may document regression of the autoantibody-mediated component of the disease, and the trend can be used as one marker of long-term monitoring. The absolute value should not be assessed in isolation, however. Not all results among the anti-CFH assays in use are fully standardized, and there is no universal cut-off for therapeutic decision-making valid across methods. For follow-up, it is therefore most appropriate to use the same validated method and assess the trend together with clinical and complement parameters.
Why is VIDIA a unique manufacturer of this test worldwide?
VIDIA offers the only commercially available CE-IVD kit for quantitative determination of anti-complement factor H antibodies. Its significance lies mainly in converting a parameter that was historically often determined using laboratory-developed methods into a standardized commercial IVD format with calibration and a quantitative result, which improves reproducibility and longitudinal patient monitoring.
What type of sample does the test require?
ELISA-VIDITEST anti-complement factor H is intended for human serum and plasma and provides a quantitative result in AU/ml.
How long does it take to get a result?
The kit uses an incubation protocol of 60/60/20 minutes at room temperature, that is 140 minutes of incubation. Sample preparation, washing and photometric reading must be added to this.
Nenašli jste, co hledáte?
Pomůžeme Vám najít vhodné diagnostické řešení
Popište nám, co potřebujete vyšetřit, a náš produktový tým Vám pomůže najít vhodné diagnostické řešení. Odpovíme Vám do 24 hodin.
Preferujete e-mail? Napište nám na obchod@vidia.cz
